1. Neuroimaging and genetic risk for Alzheimer's disease and addiction-related degenerative brain disorders
- Author
-
Paul M. Thompson, Cassandra D. Leonardo, Florence F. Roussotte, Madelaine Daianu, and Neda Jahanshad
- Subjects
Degenerative Disorder ,Imaging genetics ,Substance-Related Disorders ,Cognitive Neuroscience ,Neuroimaging ,Disease ,Article ,Behavioral Neuroscience ,Cellular and Molecular Neuroscience ,Alzheimer Disease ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Genetic Predisposition to Disease ,Neuroradiology ,Neurodegeneration ,Neuropsychology ,Brain ,Neurodegenerative Diseases ,medicine.disease ,Psychiatry and Mental health ,Neurology ,Neurology (clinical) ,Alzheimer's disease ,Psychology ,Neuroscience - Abstract
Neuroimaging offers a powerful means to assess the trajectory of brain degeneration in a variety of disorders, including Alzheimer’s disease (AD). Here we describe how multi-modal imaging can be used to study the changing brain during the different stages of AD. We integrate findings from a range of studies using magnetic resonance imaging (MRI), positron emission tomography (PET), functional MRI (fMRI) and diffusion weighted imaging (DWI). Neuroimaging reveals how risk genes for degenerative disorders affect the brain, including several recently discovered genetic variants that may disrupt brain connectivity. We review some recent neuroimaging studies of genetic polymorphisms associated with increased risk for late-onset Alzheimer’s disease (LOAD). Some genetic variants that increase risk for drug addiction may overlap with those associated with degenerative brain disorders. These common associations offer new insight into mechanisms underlying neurodegeneration and addictive behaviors, and may offer new leads for treating them before severe and irreversible neurological symptoms appear.
- Published
- 2013